Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Tune Therapeutics Inc.
Headquarters: Durham, NC, United States of America
Website: https://tunetx.com
Year Founded: 2020
Status: Private
See Emerging Company Profile .
BioCentury | Mar 21, 2025
Editor's Commentary
Solving CNS delivery will open big doors for epigenome editing: a Perspective
Epigenome editors could shine in neurology indications not served by other modalities — but only if companies invest in delivery
BioCentury | Jan 16, 2025
Finance
Megarounds for Tune, Umoja
Though most of January’s VC news came out ahead of the industry’s largest conference, a handful of biotechs announced fundings this week
BioCentury | Apr 10, 2024
Emerging Company Profile
Moonwalk: Mapping the methylome to create epigenome editors
With CRISPR pioneer Feng Zhang among its founders, Moonwalk aims to control gene expression via epigenetic editing
BioCentury | Jun 2, 2023
Product Development
Epigenome editing companies showcase progress at ASGCT
Modalis accomplishes gene activation, while Tune achieves gene repression, both in non-human primates
BioCentury | Apr 11, 2023
Management Tracks
Legend hires Koneru as CMO
Plus: Erasca promotes Morris, Lovejoy and updates from Poseida, Mithra, Tune, Cellarity and more
BioCentury | Aug 18, 2022
Product Development
Rise of the dead Cas to edit the epigenome
Start-ups are tuning gene expression by hitching a range of effector domains to catalytically dead CRISPR machinery
BioCentury | Jul 13, 2022
Emerging Company Profile
Epic Bio: Epigenome editing via compact components
Horizons Ventures leads $55M series A for start-up developing compact epigenome editors with all-in-one AAV delivery
BioCentury | Feb 2, 2022
Emerging Company Profile
BioCentury’s 2021 class of emerging companies
An innovation showcase of protein degraders, RNA therapeutics, delivery vectors and gene modifiers
BioCentury | Dec 14, 2021
Emerging Company Profile
Tune: Fine-tuning gene expression through epigenetic editing
Newco emerges with $40M to control gene expression levels by altering the 98% of the genome outside of coding regions
BioCentury | Dec 3, 2021
Product Development
Dec. 2 Quick Takes: $109M series C for Acepodia
Plus Tune catches $40M series A from NEA, Emerson, and Astellas-Dyno, Omeros, Vir and more
Items per page:
1 - 10 of 10